Kathryn E. Yost

TL;DR: Paired single-cell RNA and T cell receptor sequencing on 79,046 cells from site-matched tumors from patients with basal or squamous cell carcinoma before and after anti-PD-1 therapy demonstrates that pre-existing tumor-specific T cells may have limited reinvigoration capacity, and that the T cell response to checkpoint blockade derives from a distinct repertoire of T cell clones that may have just recently entered the tumor.

TL;DR: Analysis of scATAC-seq profiles from serial tumor biopsies before and after programmed cell death protein 1 blockade identifies chromatin regulators of therapy-responsive T cell subsets and reveals a shared regulatory program that governs intratumoral T cell exhaustion and CD4+ T follicular helper cell development.

TL;DR: It is shown that the PVT1 promoter has a tumor-suppressor function that is independent of PVT 1 lnc RNA, and regulatory sequences of lncRNA genes as potential disease-associated DNA elements are highlighted.

TL;DR: It is anticipated that droplet-based single-cell chromatin accessibility will provide a broadly applicable means of identifying regulatory factors and elements that underlie cell type and function.

TL;DR: It is reported that mural cells, which surround the endothelium and are critical for blood-brain-barrier integrity, express CD19, suggesting an on-target mechanism for neurotoxicity in CD19-directed therapies and highlighting the utility of human single-cell atlases for designing immunotherapies.